---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: PARP inhibitors for germline BRCA1 or BRCA2 variants"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: PARP inhibitors for germline BRCA1 or BRCA2 variants. Topics: PARP inhibitor recommendations in second-line treatment: ESMO 2026 guideline; PARP inhibitor recommendation for hormone receptor-positive disease: ASCO 2021 guideline; PARP inhibitors versus nonplatinum chemotherapy in BRCA1/2 carriers: ASCO, ASTRO, and SSO 2020 guideline; Comparator regulatory information: olaparib; 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/parp-inhibitors-for-germline-brca1-or-brca2-variants"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: PARP inhibitors for germline BRCA1 or BRCA2 variants

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 PARP Inhibitors for Germline BRCA1 or BRCA2 Variants

<a id="topic-2.2.2.1.5-1"></a>

### PARP inhibitor recommendations in second-line treatment: ESMO 2026 guideline

> “Poly (ADP-ribose) polymerase inhibitor (PARPi) monotherapy is recommended for patients with a germline BRCA1/2 mutation [I, A].”
> “Options include olaparib (ESMO-MCBS v2.0 score: 4) or talazoparib (ESMO-MCBS v2.0 score: 3).”
> “Olaparib or talazoparib can be recommended for patients with a germline PALB2 mutation [II, B; not European Medicines Agency (EMA) or Food and Drug Administration (FDA) approved].”
> “For patients with tumours harbouring somatic pathogenic or likely pathogenic BRCA1/2 mutations, PARPi monotherapy can also be recommended [II, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.1.5-2"></a>

### PARP inhibitor recommendation for hormone receptor-positive disease: ASCO 2021 guideline

> “Patients with HR-positive MBC with germline BRCA mutations no longer benefiting from endocrine therapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy.”

Source: [Moy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34324366/)

<a id="topic-2.2.2.1.5-3"></a>

### PARP inhibitors versus nonplatinum chemotherapy in BRCA1/2 carriers: ASCO, ASTRO, and SSO 2020 guideline

> “Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers.”
> “Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/2 carriers.”

Source: [Tung et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32243226/)

<a id="topic-2.2.2.1.5-4"></a>

### Comparator regulatory information: olaparib

> “Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.”
> “The recommended dosage of Lynparza is 300 mg taken orally twice daily, with or without food.”
> “Patients with hormone receptor-positive disease must have progressed on at least 1 endocrine therapy (adjuvant or metastatic), or have disease that the treating healthcare provider believed to be inappropriate for endocrine therapy.”
> “Discontinuation due to an adverse reaction occurred in 5% of patients receiving Lynparza.”

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

### Comparator regulatory information: talazoparib

> “TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.”
> “The median duration of study treatment was 6.1 months in patients who received TALZENNA and 3.9 months in patients who received chemotherapy.”
> “Serious adverse reactions of TALZENNA occurred in 32% of patients.”
> “Permanent discontinuation due to adverse reactions occurred in 5% of TALZENNA patients.”

Source: [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

### Prevalence of germline BRCA1 or BRCA2 variants in breast cancer: OlympiAD final analysis

> “Approximately 5% of all breast cancer patients carry a germline deleterious mutation in BRCA1 and/or BRCA2 (BRCAm), with higher rates among those with human epidermal growth factor receptor 2 (HER2)-negative disease”

Source: [Robson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6503629/)

<a id="topic-2.2.2.1.5-7"></a>

### Olaparib versus chemotherapy: OlympiAD progression-free survival, response, and safety

> “Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive standard therapy.”
> “Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001).”
> “The response rate was 59.9% in the olaparib group and 28.8% in the standard-therapy group.”
> “The rate of grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the standard-therapy group, and the rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, respectively.”

Source: [Robson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28578601/)

<a id="topic-2.2.2.1.5-8"></a>

### Olaparib versus chemotherapy: OlympiAD final overall survival

> “At 64% data maturity, median OS was 19.3 months with olaparib versus 17.1 months with TPC (HR 0.90, 95% CI 0.66–1.23; P = 0.513); median follow-up was 25.3 and 26.3 months, respectively.”
> “receptor status (triple negative: 0.93, 0.62–1.43; hormone receptor positive: 0.86, 0.55–1.36)”
> “While there was no statistically significant improvement in OS with olaparib compared to TPC, there was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease.”

Source: [Robson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6503629/)

<a id="topic-2.2.2.1.5-9"></a>

### Talazoparib versus chemotherapy: EMBRACA progression-free survival, response, and safety

> “Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy.”
> “Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001).”
> “The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001).”
> “Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively.”

Source: [Litton et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30110579/)

<a id="topic-2.2.2.1.5-10"></a>

### Talazoparib versus chemotherapy: EMBRACA final overall survival

> “As the population was either triple-negative or hormone receptor-positive within EMBRACA, the effect of talazoparib on OS in these two subgroups was generally consistent, with HR 0.899 (95% CI 0.634–1.276) for triple-negative patients and HR 0.827 (95% CI 0.597–1.143) for hormone receptor-positive patients.”
> “Altogether, a similar percentage of patients received subsequent systemic antineoplastic therapy in the talazoparib and chemotherapy groups (80.8% and 76.4%, respectively)”

Source: [Litton et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10649377/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
